MARKET

FPRX

FPRX

Five Prime
NASDAQ

Real-time Quotes | Nasdaq Last Sale

37.79
-0.21
-0.55%
Opening 12:22 03/05 EST
OPEN
37.87
PREV CLOSE
38.00
HIGH
37.95
LOW
37.70
VOLUME
6.39M
TURNOVER
--
52 WEEK HIGH
38.18
52 WEEK LOW
1.750
MARKET CAP
1.66B
P/E (TTM)
-14.0803
1D
5D
1M
3M
1Y
5Y
Amgen (AMGN) to Add Stomach Cancer Drug With Five Prime Buyout
Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline.
Zacks · 1h ago
ETFs to Tap Amgen's Drive for Cancer Deal
Amgen (AMGN) has agreed to buy Five Prime Therapeutics (FPRX) for $1.9 billion.
Zacks · 2h ago
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4)
Benzinga · 4h ago
DJ Five Prime Therapeutics Cut to Hold From Buy by Jefferies
Dow Jones · 4h ago
DJ Five Prime Therapeutics Price Target Announced at $38.00/Share by Jefferies
Dow Jones · 4h ago
Five Prime Therapeutics (FPRX) Stock Jumps 78.7%: Will It Continue to Soar?
Five Prime Therapeutics (FPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks · 4h ago
Amgen Inks $1.9B Deal To Buy Five Prime Therapeutics; Shares Pop 79%
Amgen has agreed to snap up clinical-stage biotech Five Prime Therapeutics for an equity value of $1.9 billion, to strengthen the company’s oncology candidates. Five Prime shares surged 78.7% to close at $38 on March 4, while Amgen shares declined almost 1...
SmarterAnalyst · 8h ago
Analyst Actions: Jefferies Downgrades Five Prime Therapeutics to Hold From Buy; Price Target is $38
MT Newswires · 10h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FPRX. Analyze the recent business situations of Five Prime through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FPRX stock price target is 30.43 with a high estimate of 38.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 196
Institutional Holdings: 40.15M
% Owned: 91.46%
Shares Outstanding: 43.90M
TypeInstitutionsShares
Increased
41
7.52M
New
72
14.34M
Decreased
24
9.10M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.51%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
President/Chief Executive Officer
Thomas Civik
Chief Financial Officer/Executive Vice President
David Smith
Executive Vice President
Helen Collins
Secretary
Francis Sarena
Independent Director
Franklin Berger
Independent Director
Kapil Dhingra
Independent Director
Peder Jensen
Independent Director
Lori Lyons-Williams
Independent Director
Garry Nicholson
Independent Director
Carol Schafer
No Data
  • All
  • Financials
  • Insiders
More
About FPRX
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company’s pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.

Webull offers kinds of Five Prime Therapeutics Inc stock information, including NASDAQ:FPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FPRX stock methods without spending real money on the virtual paper trading platform.